Rigel’s Tavalisse Hits Pothole In Label Expansion For Hemolytic Anemia
Executive Summary
Tavalisse misses the primary endpoint in a 90-patient Phase III trial in warm autoimmune hemolytic anemia, but Rigel contends a high placebo response in Eastern Europe confounded the results.
You may also be interested in...
Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
Rigel Readies Tavalisse For Late-May Launch After FDA Approval
Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.
Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.